Globe Newswire

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Fastly, Inc. (“Fastly” or the “Company”) (NYSE: FSLY) for violations of the federal securities laws on behalf of investors who purchased or acquired Fastly common stock between February 15, 2024 and May 1, 2024, inclusive (the “Class Period”).

On May 24, 2024, a... (continue reading...)

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.

Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process:

• ... (continue reading...)

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) for violations of the federal securities laws on behalf of investors who purchased or acquired Vestis common stock between October 2, 2023 and May 1, 2024, inclusive (the “Class Period”).

On May 17, 2024, a... (continue reading...)

Paris, 31 May 2024 - 5:45 pm

On 13 February 2024, Rubis announced a capital increase reserved for eligible employees of the companies belonging to the Corporate Savings Plan, Rubis Avenir. The maximum nominal amount authorised by the Shareholders’ Meeting of 8 June 2023 was €700,000 (560,000 Rubis shares).

The subscription price was set at €15.71, which, pursuant to Article L. 3332-19 of the French Labour Code, represents 70% of the average... (continue reading...)

• If approved, IXCHIQ® will become the first vaccine available in the EU against the chikungunya virus (CHIKV)
• Decision on EU marketing authorization expected in the third quarter of 2024

Saint Herblain (France), May 31, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending... (continue reading...)